Citations (40)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Philip A Levin. (2016) Practical combination therapy based on pathophysiology of type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity 9, pages 355-369.
Read now
Read now
George S Panagoulias & John Doupis. (2014) Clinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combination. Patient Preference and Adherence 8, pages 227-236.
Read now
Read now
Giuseppe Derosa & Pamela Maffioli. (2011) Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity 4, pages 263-271.
Read now
Read now
Alberto Verrotti, Rosa Maria Chiuri, Annalisa Blasetti, Angelika Mohn & Francesco Chiarelli. (2010) Treatment options for paediatric diabetes. Expert Opinion on Pharmacotherapy 11:15, pages 2483-2495.
Read now
Read now
Pedro de Pablos-Velasco. (2010) Pioglitazone: beyond glucose control. Expert Review of Cardiovascular Therapy 8:8, pages 1057-1067.
Read now
Read now
Lalit S Doshi, Manoja Kumar Brahma, Umakant A Bahirat, Amol V Dixit & Kumar VS Nemmani. (2010) Discovery and development of selective PPARγ modulators as safe and effective antidiabetic agents. Expert Opinion on Investigational Drugs 19:4, pages 489-512.
Read now
Read now
Christina Voulgari & Nicholas Tentolouris. (2009) Combination of nateglinide with thiazolidinediones in Type 2 diabetes. Expert Review of Endocrinology & Metabolism 4:6, pages 537-552.
Read now
Read now
Articles from other publishers (33)
Ulrike Meyer-Lindemann, Aldo Moggio, Alexander Dutsch, Thorsten Kessler & Hendrik B. Sager. (2023) The Impact of Exercise on Immunity, Metabolism, and Atherosclerosis. International Journal of Molecular Sciences 24:4, pages 3394.
Crossref
Crossref
Amedeo Vetere, Vishal S. Parekh, Ashley E. Modell, Veronika M. Shoba, Amit Choudhary & Bridget K. Wagner. 2022. Nanotechnology for Diabetes Management. Nanotechnology for Diabetes Management
1
52
.
Kuan-Yuan Chen, Sheng-Ming Wu, Chien-Hua Tseng, Kang-Yun Lee, Yu-Huei Lin, Hung-Yi Liu & Li-Nien Chien. (2021) Combination therapies with thiazolidinediones are associated with a lower risk of acute exacerbations in new-onset COPD patients with advanced diabetic mellitus: a cohort-based case–control study. BMC Pulmonary Medicine 21:1.
Crossref
Crossref
Olakunle Sanni & G. Terre’Blanche. (2021) Therapeutic potentials of agonist and antagonist of adenosine receptors in type 2 diabetes. Reviews in Endocrine and Metabolic Disorders 22:4, pages 1073-1090.
Crossref
Crossref
John C. Clapham. 2020. Type 2 Diabetes. Type 2 Diabetes
1
30
.
Atsuo Tahara & Toshiyuki Takasu. (2019) SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model. Physiological Reports 7:22.
Crossref
Crossref
Chin-Hsiao Tseng. (2019) Rosiglitazone has a neutral effect on the risk of dementia in type 2 diabetes patients. Aging 11:9, pages 2724-2734.
Crossref
Crossref
Lu Han, Wen-Jun Shen, Stefanie Bittner, Fredric B Kraemer & Salman Azhar. (2017) PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-α. Future Cardiology 13:3, pages 259-278.
Crossref
Crossref
W. Gao, Q. Wang & S. Yu. (2016) Efficacy, safety and impact on β-cell function of dipeptidyl peptidase-4 inhibitors plus metformin combination therapy in patients with type 2 diabetes and the difference between Asians and Caucasians: a meta-analysis. Journal of Endocrinological Investigation 39:9, pages 1061-1074.
Crossref
Crossref
Kay L.H. WuYung-Mei ChaoShiow-Jen TsayChen Hsiu ChenSamuel H.H. ChanIma DovinovaJulie Y.H. Chan. (2014) Role of Nitric Oxide Synthase Uncoupling at Rostral Ventrolateral Medulla in Redox-Sensitive Hypertension Associated With Metabolic Syndrome. Hypertension 64:4, pages 815-824.
Crossref
Crossref
Chin-Hsiao Tseng. (2014) Pioglitazone does not affect the risk of kidney cancer in patients with type 2 diabetes. Metabolism 63:8, pages 1049-1055.
Crossref
Crossref
L. Masmiquel. (2014) Efectos cardiovasculares y seguridad de los fármacos hipoglucemiantes: situación actual. SEMERGEN - Medicina de Familia 40:2, pages 80-88.
Crossref
Crossref
Amanda Carla Quintas de Medeiros Vieira, Graziella Silvestre Marques, Cybelly Marques de Melo, Keyla Emanuelle Ramos da Silva, Larissa Araújo Rolim, Maria do Carmo Alves de Lima, Suely Lins Galdino, Ivan da Rocha Pitta & Pedro José Rolim Neto. (2013) Physical–chemical characterization of new anti-inflammatory agent (LPSF/GQ-130) and evaluation of its thermal compatibility with pharmaceutical excipients. Journal of Thermal Analysis and Calorimetry 115:3, pages 2339-2349.
Crossref
Crossref
D. Wu, L. Li & C. Liu. (2014) Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes, Obesity and Metabolism 16:1, pages 30-37.
Crossref
Crossref
A. Consoli & G. Formoso. (2013) Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?. Diabetes, Obesity and Metabolism 15:11, pages 967-977.
Crossref
Crossref
Yingji Wang, Lei Yu, Ningren Cui, Xin Jin, Daling Zhu & Chun Jiang. (2013) Differential sensitivities of the vascular KATP channel to various PPAR activators. Biochemical Pharmacology 85:10, pages 1495-1503.
Crossref
Crossref
André J. Scheen. (2012) Outcomes and lessons from the PROactive study. Diabetes Research and Clinical Practice 98:2, pages 175-186.
Crossref
Crossref
Rania A. Elrashidy, Mervat E. Asker & Hoda E. Mohamed. (2012) Pioglitazone Attenuates Cardiac Fibrosis and Hypertrophy in a Rat Model of Diabetic Nephropathy. Journal of Cardiovascular Pharmacology and Therapeutics 17:3, pages 324-333.
Crossref
Crossref
Lei Yu, Xin Jin, Ningren Cui, Yang Wu, Zhenda Shi, Daling Zhu & Chun Jiang. (2012)
Rosiglitazone selectively inhibits K
ATP
channels by acting on the K
IR
6 subunit
. British Journal of Pharmacology 167:1, pages 26-36.
Crossref
Crossref
Rania A Elrashidy, Mervat E Asker & Hoda E Mohamed. (2012) Beneficial effects of pioglitazone against cardiovascular injury are enhanced by combination with aliskiren in a rat model of diabetic nephropathy. Journal of Pharmacy and Pharmacology 64:6, pages 862-871.
Crossref
Crossref
Giuseppe DerosaPamela Maffioli. (2012) Dipeptidyl Peptidase-4 Inhibitors: 3 Years of Experience. Diabetes Technology & Therapeutics 14:4, pages 350-364.
Crossref
Crossref
Giuseppe Derosa. (2011) Pioglitazone is a Valid Alternative to Rosiglitazone. American Journal Cardiovascular Drugs 11:6, pages 357-362.
Crossref
Crossref
Lei Yu, Xin Jin, Yang Yang, Ningren Cui & Chun Jiang. (2011) Rosiglitazone inhibits vascular KATP channels and coronary vasodilation produced by isoprenaline. British Journal of Pharmacology 164:8, pages 2064-2072.
Crossref
Crossref
Anthony H. Barnett & Jenny GriceAnthony H. Barnett & Jenny Grice. 2011. New Mechanisms in Glucose Control. New Mechanisms in Glucose Control
7
16
.
Abd A Tahrani, Clifford J Bailey, Stefano Del Prato & Anthony H Barnett. (2011) Management of type 2 diabetes: new and future developments in treatment. The Lancet 378:9786, pages 182-197.
Crossref
Crossref
A. Pfützner, E. Paz-Pacheco, E. Allen, R. Frederich & R. Chen. (2011) Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity and Metabolism 13:6, pages 567-576.
Crossref
Crossref
Priscilla L Hollander, Jia Li, Robert Frederich, Elsie Allen & Roland Chen. (2011) Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus. Diabetes and Vascular Disease Research 8:2, pages 125-135.
Crossref
Crossref
María-Nieves Sanz, Carlos Sánchez-Martín, Dominique Detaille, Guillaume Vial, Michel Rigoulet, Mohammed-Yehia El-Mir & Gloria Rodríguez-Villanueva. (2011) Acute Mitochondrial Actions of Glitazones on the Liver: a Crucial Parameter for their Antidiabetic Properties. Cellular Physiology and Biochemistry 28:5, pages 899-910.
Crossref
Crossref
Christina Schwanstecher & Mathias Schwanstecher. 2011. Diabetes - Perspectives in Drug Therapy. Diabetes - Perspectives in Drug Therapy
1
33
.
Alexandra Peyser, Nathaniel MacHardy, Freya Tarapore, Jacqueline MacHardy, Leslie Powell, Debbie S Gipson, Virginia Savin, Cynthia Pan, Theresa Kump, Suzanne Vento & Howard Trachtman. (2010) Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group. BMC Nephrology 11:1.
Crossref
Crossref
Amanda T. White & Anne N. Murphy. (2010) Administration of thiazolidinediones for neuroprotection in ischemic stroke: a pre-clinical systematic review. Journal of Neurochemistry 115:4, pages 845-853.
Crossref
Crossref
Aydin Unal, Ismail Kocyigit, Murat Hayri Sipahioglu, Bulent Tokgoz, Oktay Oymak, Nilufer Oguzhan & Cengiz Utas. (2010) Syndrome of Inappropriate Antidiuretic Hormone Secretion and Severe Hyponatremia Due to Pioglitazone. The Endocrinologist 20:6, pages 277-278.
Crossref
Crossref
Salman Azhar. (2010) Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease. Future Cardiology 6:5, pages 657-691.
Crossref
Crossref